Vivos Therapeutics

VVOS

Market cap $19.2M

Vivos Therapeutics, Inc. ( VVOS ) Q3 2025 Earnings Call November 19, 2025 5:00 PM EST Company Participants Bradford Amman - CFO, Treasurer & Secretary R. Huntsman - Co-Founder, Chairman of the Board & CEO Conference Call Participants Lucas Ward - Ascendiant Capital Markets LLC, Research Division Robert Sassoon - Water Tower Research LLC Presentation Operator Good day, everyone, and welcome to the Vivos Third Quarter 2025 Conference Call.

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today reported financial results and operating highlights for the three and nine months ended September 30, 2025.

LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025.

Vivos Therapeutics, Inc. ( VVOS ) Shareholder/Analyst Call November 4, 2025 12:00 PM EST Company Participants R. Huntsman - Co-Founder, Chairman of the Board & CEO Bradford Amman - CFO, Treasurer & Secretary Jennifer Hauser Conference Call Participants Donna M.

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today released previously unpublished clinical data confirming that treatment with Vivos' FDA-cleared Daytime-Nighttime Appliance (DNA) can provide children with Attention-Deficit/Hyperactivity Disorder (ADHD) and OSA significant relief and improvement in their quality of life.

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA.

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2025 Earnings Conference Call August 19, 2025 5:00 PM ET Company Participants Bradford K. Amman - CFO, Treasurer & Secretary R.

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of  highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the three and six months ended June 30, 2025.

LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025.

LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos' patented Daytime-Nighttime Appliance (DNA).